Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;38(6):451-454.
doi: 10.1089/aid.2021.0202. Epub 2022 Mar 23.

Short Communication:Outcomes of Dual Versus Triple Antiretroviral Drug Regimens Among Virally Suppressed Adults in the DC Cohort

Wei Li Adeline Koay  1   2 , Jiayang Xiao  3 , Marinella Temprosa  3 , Lindsey P Happ  4 , Anne K Monroe  4 , Amanda D Castel  4 , Natella Y Rakhmanina  1   2   5 ; DC Cohort Executive Committee
Collaborators, Affiliations

Short Communication:Outcomes of Dual Versus Triple Antiretroviral Drug Regimens Among Virally Suppressed Adults in the DC Cohort

Wei Li Adeline Koay et al. AIDS Res Hum Retroviruses. 2022 Jun.

Abstract

This study explored virological outcomes of two-drug (2DRs) and three-drug (3DRs) antiretroviral regimens in adults with HIV in the DC Cohort. We analyzed 310 treatment-experienced adults with sustained HIV RNA ≤50 copies/mL at baseline, 53 of whom switched to 2DRs and 257 continued 3DRs. Adults on 2DRs and 3DRs had similar demographics (median age 53.3 years, 76.8% cisgender male, 76.1% Black). Adults on 2DRs had more participants with ≥2 comorbidities (62.3% vs. 42.8%, p = .019), had a longer time since HIV diagnosis (median years 20.4 vs. 13.2, p = .017), and received the regimen of interest for a shorter duration (median years 1.3 vs. 3.3, p < .001) compared with adults on 3DRs. Adults receiving 2DRs had a higher, although nonsignificant, risk for virological failure (two consecutive HIV RNA ≥50 copies/mL) at 24 months follow-up than adults on 3DRs (6.7% vs. 1.7%, respectively; p = .10). Future analysis of the effectiveness of 2DRs is needed.

Keywords: HIV; antiretroviral therapy; dual therapy; regimen simplification; two-drug regimen.

PubMed Disclaimer

Conflict of interest statement

No competing financial interests exist.

Figures

FIG. 1.
FIG. 1.
Time to virological failure for participants with sustained viral suppression at the time of study entry, stratified by 2DRs and 3DRs. Top: Cumulative incidence of virological failure over time. Solid line: Participants on 2DRs. Dotted line: Participants on 3DRs. Bottom: Number of participants at risk for virological failure over time. 2DRs, two-drug regimens; 3DRs, three-drug regimens.
See this image and copyright information in PMC

References

    1. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Ad..., accessed August 27, 2021.
    1. European AIDS Clinical Society: EACS Guidelines Version 10.1 October 2020. Available at https://www.eacsociety.org/media/guidelines-10.1_30032021_1.pdf, accessed August 27, 2021.
    1. Cahn P, Madero JS, Arribas JR, et al. : Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): Week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 2019;393:143–155. - PubMed
    1. Aboud M, Orkin C, Podzamczer D, et al. : Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV 2019;6:e576–e587. - PubMed
    1. Pierone G, Henegar C, Fusco J, et al. : Two-drug antiretroviral regimens: An assessment of virologic response and durability among treatment-experienced persons living with HIV in the OPERA((R)) Observational Database. J Int AIDS Soc 2019;22:e25418. - PMC - PubMed

Publication types